Barlogie, B., Pineda-Roman, M., van Rhee, F., Haessler, J., Anaissie, E., Hollmig, K., . . . Crowley, J. (2008). Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. American Society of Hematology.
शिकागो स्टाइल उद्धरणBarlogie, Bart, et al. Thalidomide Arm of Total Therapy 2 Improves Complete Remission Duration and Survival in Myeloma Patients With Metaphase Cytogenetic Abnormalities. American Society of Hematology, 2008.
एमएलए उद्धरणBarlogie, Bart, et al. Thalidomide Arm of Total Therapy 2 Improves Complete Remission Duration and Survival in Myeloma Patients With Metaphase Cytogenetic Abnormalities. American Society of Hematology, 2008.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.